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Abstract
Several biocompatible polymers are capable of large responses to small temperature changes around 37ºC. In
water, their responses include shrinkage and swelling as well as transitions in wettability. These properties have
been harnessed for biomedical applications such as tissue engineering scaffolds and drug delivery carriers. A
soft material/hard material hybrid in which a magnetic metal or oxide is embedded in a temperature-
responsive polymer matrix can combine the thermal sensitivity with magnetic signatures. Importantly,
nanosizing such construct brings about new desirable features of extremely fast thermal response time, small
magnetic hysteresis and enhanced magnetic susceptibility. Remote magnetic maneuvering and heating of the
hybrid nanocolloids makes possible such applications as high-throughput enzyme separation and cell
screening. Robust drug release on demand may also be obtained using these colloids and nanoparticle-derived
thin film devices of combined thermal magnetic sensitivity.
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Summary Several biocompatible polymers are capable of large responses to small temper-
ature changes around 37 ◦C. In water, their responses include shrinkage and swelling as well
as transitions in wettability. These properties have been harnessed for biomedical applications
such as tissue engineering scaffolds and drug delivery carriers. A soft material/hard material
hybrid in which a magnetic metal or oxide is embedded in a temperature-responsive polymer
matrix can combine the thermal sensitivity with magnetic signatures. Importantly, nanosizing
such construct brings about new desirable features of extremely fast thermal response time,
small magnetic hysteresis and enhanced magnetic susceptibility. Remote magnetic maneuver-
ing and heating of the hybrid nanocolloids makes possible such applications as high-throughput
enzyme separation and cell screening. Robust drug release on demand may also be obtained
using these colloids and nanoparticle-derived thin ﬁlm devices of combined thermal magnetic
sensitivity.
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Introduction23
Smart materials responsive to multiple environmental stim-24
uli are of interest to biotechnology because of possible25
applications such as delivery carriers, separation plat-26
forms and environment sensors. Since body temperature27
is nearly constant, a small temperature excursion about28
it provides an environmental stimulus to be exploited.29
Temperature-responsive soft materials used in conjunction30
with localized heating (e.g., via hyperthermia) are there-31
fore prime candidates for biomedical applications [1]. Other32
stimuli such as pH, glucose, stress or strain, and electro-33
magnetic ﬁelds can be combined with thermal stimulus to34
create a multi-stimuli-responsive system. Here we focus on35
magnetic stimulus which can be applied remotely. One pos-36
sible application of magnetically and thermally responsive37
smart nanomaterials is illustrated in Fig. 1 that pertains to38
remotely controlled drug delivery.39
Since none of the soft materials suitable for biomedi-40
cal applications is magnetic, a soft—hard hybrid construct is41
required to combine magnetic and thermal sensitivities. The42
soft temperature-responsive materials of choice are those43
that form hydrogel [2], which is a three-dimensional net-44
work of polymer that retains its structure while being water45
absorbent; i.e., it swells, but does not dissolve, in water.46
Common biomedical uses of hydrogels include soft contact47
lenses made of silicone or polyacrylamide and medical elec-48
trodes made of polyethylene oxide. In some hydrogels, it is49
Figure 1 Two drug release mechanisms under magnetic heating. Gentle magnetic heating causes temperature-responsive polymer
to shrink, squeezing drug out from the nanoparticle. Intense magnetic heating additionally ruptures the nanoparticle, triggering a
burst-like drug release.
possible to couple water absorption and network deforma- 50
tion to a temperature-stimulated phase transition, so the 51
temperature response may be manifested as a large change 52
in the shape, rigidity, water content or hydrophobicity of 53
the gel. The hard magnetic material of choice is iron oxide, 54
which is relatively safe for biomedical applications and can 55
be readily synthesized in a form of small particles to be 56
embedded into the soft material. Iron oxide can be attracted 57
to a magnet. Moreover, using a high-frequency ﬁeld remote 58
magnetic heating of iron oxide becomes possible thereby 59
converting a magnetic stimulus to a thermal stimulus. 60
Nanotechnology offers several advantages to these mate- 61
rials. Nanoparticles of iron oxide do not have multiple 62
domains found in larger magnets; the unit-cell spins 63
of the entire nanoparticle line up and act as a sin- 64
gle ‘‘super’’ spin that aligns more perfectly with the 65
applied ﬁeld giving rise to a higher magnetic susceptibility. 66
This ‘‘superparamagnetism’’ unique to nanoparticles pro- 67
vides a stronger magnetic response than bulk magnetism. 68
Meanwhile, breathing water in a temperature-responsive 69
hydrogel is easier for nanoparticles because of shorter trans- 70
port distance, so their response to a temperature stimulus is 71
much faster than that of a bulk hydrogel. In addition, smaller 72
hybrid particles form more stable colloids and they circulate 73
better in the body; at the same time they can more easily 74
penetrate and accumulate in the leaky, defective archi- 75
tecture of growing, vascularizing tumors [3,4]. Nanosized 76
iron oxide and polymer particles can also be more readily
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Biomedical nanoparticle carriers 3
digested in the body through biodegradation and clearance77
[5]. On the other hand, the stability of the nanoparticle78
construct and its cargo against chemical dissolution and79
degradation may be questionable. Moreover, the magnetic80
force on nanoparticle is very small because of small mass. In81
the following we will discuss the current status and under-82
standing of the nanoscale hybrid systems which have been83
developed to exploit these thermal and magnetic responses84
for biomedical applications.85
Temperature-responsive polymers86
Like all materials polymers manifest thermodynamic struc-87
tural transitions along with associated physical or chemical88
responses. These changes are categorized by the phase dia-89
grams. Polymers, however, are unique in that their solutions90
may thermodynamically separate into two distinct phases at91
high temperatures, whereas in other materials such phase92
separations usually occur at low temperatures. Of special93
interest for biomedical applications is the behavior of a poly-94
mer—water solution which is stable below a so-called lower95
critical solution temperature (LCST), above which the solu-96
tion partitions into two phases: water and a polymer-rich97
phase. This is in contrast to the phase separation below98
an upper critical solution temperature (UCST) that is more99
commonly encountered in non-polymer systems. Such LCST100
exists for both homopolymers and block copolymers. Some101
common ones are listed in Table 1.102
Among the homopolymers that exhibit LCST, the most103
studied is poly(N-isopropylacrylamide) (poly(NIPPAm) or104
PNIPPAm) [6] (Fig. 2a) in which the LCST behavior repre-105
sents a coil-to-globule transition in the shape of a hydrated106
polymer chain [7]. At low temperature, the chain solubilizes107
water which keeps the chain extended. At higher temper-108
ature, the lost entropy of the ordered water around the109
chain becomes energetically costly, so the water leaves110
for the bulk and the coil collapses under the hydropho-111
bic force between polymer segments. Slightly crosslinked112
NIPPAm is therefore a thermally responsive hydrogel that113
shrinks above the LCST by rejecting water from the polymer114
Figure 2 Chemical formula of two polymers that exhibit
LCST. (a) PNIPAAm homopolymer and (b) PEO—PPO—PEO triblock
copolymer.
network. Poly(N-vinylcaprolactam) (PVCL) is another exten- 115
sively studied homopolymer with a similar LCST behavior 116
[8]. 117
Among block copolymers, the most studied are the 118
poly(ethylene oxide)—poly(propylene oxide)—poly(ethylene 119
oxide) (PEO—PPO—PEO) triblock copolymers [9] (Fig. 2b). 120
PEO, also known as PEG, is frequently present as a biocom- 121
patible hydrophilic coating on nanoparticles to improve their 122
in vivo circulation [10]; PPO, on the other hand, is more 123
hydrophobic. Commercially known as Pluronics® (BASF) or 124
poloxamers® (ICI) this amphiphilic polymer is a non-ionic 125
surfactant because within each chain the PEO blocks and 126
the PPO blocks can self-segregate into hydrophilic and 127
hydrophobic domains, respectively. Above the LCST, inter- 128
chain aggregation also occurs, forming alternating PEO and 129
PPO layers arranged into micelles (with a hydrophobic PPO 130
core and a hydrophilic PEO shell), cylinders, lamellas or 131
other supramolecular structures [11]. In this sense, the 132
LCST also represents the critical micellization tempera- 133
ture (CMT) [12—13]. Stabilized supramolecular structures of 134
PEO—PPO—PEO (via chemical crosslinking, physical entan- 135
glement with another interpenetrating polymer network, or 136
adsorption to a water/oil interface) undergo a volumetric 137
transition at the LCST due to water solubilization/rejection 138
in the PPO layer. Moreover, at higher concentrations swollen 139
micelles may gel reﬂecting an ordering tendency akin 140
to colloidal crystallization which maximizes the free vol- 141
ume, hence entropy, around individual micelles. Some 142
PEO—PPO—PEO polymers listed in Table 1 have an LCST close 143
to the physiological temperature (37 ◦C). 144
Natural biopolymers generally exhibit multiple structural 145
transitions at increasing temperatures, some causing large 146
shape changes. For example, a single strand polypeptide can 147
reversibly transform from a helix to a coil above a character- 148
istic temperature, and two helical strands of complementary 149
DNA reversibly dissociate when heated above the ‘‘melting’’ 150
temperature. Such changes of secondary and tertiary struc- 151
tures of natural biopolymers have a profound effect on 152
their biological functionalities. The helix-to-coil transition 153
is not the LCST type, however, unlike the coil-to-globule 154
transition in PNIPPAm. This is because the conformation 155
change from helix to coil [14] is mainly controlled by 156
hydrogen bonding between amino acids (base pairs) and 157
is relatively immune to the entropy-dominated inﬂuences 158
of solubilization and hydrophobicity. So the UCST here is 159
essentially the ‘‘melting’’ temperature of the hydrogen 160
bond (between a carbonyl oxygen and an amine hydrogen). 161
Synthetic block copolypeptides containing hydrophobic and 162
hydrophilic blocks have also been synthesized to exploit 163
their thermal responses. Hydrophobic blocks in these diblock 164
and triblock copolypeptides typically appear as -helices 165
or -sheets, whereas random coils serve as the hydrophilic 166
blocks. However, unlike PEO—PPO—PEO block copolymers 167
that form micelles, lamellas or other ordered supramolec- 168
ular structures, the aggregation of hydrophobic blocks in 169
these copolypeptides commonly leads to long range gela- 170
tion forming an ‘‘amorphous’’ hydrogel instead [15,16]. For 171
example, between two helices of the ‘‘leucine zipper’’ type 172
the aggregation takes the form of side-wise lineup of the 173
two helices, providing physical (as opposed to chemical) 174
crosslinks for the gel [17]. The thermal behavior of these 175
hydrogels is again the non-LCST type since they ‘‘melt’’ at 176
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Table 1 Thermal transitions of selected homopolymers, their modiﬁed copolymers, Pluronics®, synthetic elastin-like polypeptides and natural polymers.
Homopolymers Modiﬁed copolymers Pluronic® series and similar triblock
copolymers
Natural polymersa
Materials LCST (◦C) Materials LCST (◦C) Materials CMT (◦C) Materials Tgel—sol (◦C)a
Poly(N-isopropylacrylamide),
PNIPAAm [71]
30—34 Poly(NIPAAm-co-AAm)
[1,21]
35—55 L64 [12] 24—45 Gelatin/collagen
[48,49]
∼40
Poly(N-vinylcaprolactam),
PVCL [2,71,74]
25—50 Poly(NIPAAm-co-N-
tBAAm)
[1]
<30 P65 [12] 26—49 Polysaccharides
[2,86]
30—50
Poly(vinyl methyl ether), PVME
[71]
37 PNIPAAm—PEG [77,78] 30—39 F68 [12] 27—53 Natural polymersb
Poly(N,N-diethylacrylamide),
PDEAAm [56,71]
25—34 PNIPAAm—CA—PCL [67] 37—38 P84/P85
[12]
19—47 Materials Tsol—gelb (◦C)
Poly(methacrylic acid), PMAA
[2]
∼75 PNIPAAm-b-PMMA/PBMA
[79,31]
32—35 F88 [12] 22—53 Methylcellulose,
MC [2]
∼80
Poly(vinyl methyl oxazolidone),
PVMO [2]
∼65 P(NIPAAm-co-SMA) [80] ∼40 P103/P104/P105
[12]
18—32 Hydroxypropylcellulose,
HPC [2]
∼55
poly(dimethylaminoethyl
methacrylate), PDMAEMA
[75]
∼50 Poly(NIPAAm-co-DMAAm)
[81]
32—44 F108 [12] 21—41 Polyphosphazene
derivatives [2]
33—100
poly(N-(L)-(1-hydroxymethyl)
propylmethacrylamide) [76]
∼30 Poly(NIPAAm)-PL(G)A
[68,69]
34—50 P123 [12] 13—26 Elastin-like polypeptides (ELPs)
Poly(silamine) [2] ∼37 poly(NIPAAm-co-HPMAm)
series [82]
10—50 F127 [12] 20—36 Materials LCST (◦C)
Poly(siloxyethylene glycol) [2] 10—60 PUA-b-PNIPAAm [83] ∼31 PEO—PLA—PEO
[60]
19—32 Poly(GVGVP)
[71,74]
28—30
Poly(vinyl alcohol), PVA [2] ∼125 Peptide-modiﬁed
P(NIPAAm-co-AAc) [84]
∼34 PEO—PHA—PEO
[85]
22—45 Poly(GVG(50%
Val-30% Gly-20%
Ala)P) [21,74]
40—42
Poly(vinyl pyrrolidone), PVP [2] ∼160 PVCL-g-PTHF [2] 35—50 PEO—PEA—PEO
[85]
14—44 Poly(GVG(6%
Val-50% Gly-44%
Ala)P) [21]
67
a Most natural polymers form a gel phase below Tgel—sol. At high temperatures, they have a random coil conﬁguration forming a sol. At low temperature, renaturation to the triple helical
conformation in gelatin and the double helical conformation in polysaccharides drives the formation of physical junctions, causing gelation.
b Some natural biopolymers (e.g., cellulose) undergo reverse thermogelation (gelation at elevated temperature from a sol state at low temperature) at Tsol—gel.
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Biomedical nanoparticle carriers 5
high temperatures by breaking loose the crosslinks. Similar177
non-LCST behavior is found in natural hydrogels and some178
examples are listed in Table 1. When gelatin is cooled below179
the gelation temperature, random coils of polypeptides180
self-assemble into triple-helices of the collagen structure,181
providing crosslinks [18]. In this case, both hydrogen bonding182
and hydrophobic aggregation contribute to gelation.183
Since any protein solution eventually precipitates at184
sufﬁciently high temperatures, hydrophobic collapse of185
the polypeptide backbone must be ultimately inevitable.186
Indeed, linear polypeptides made of monomers of a single187
amino acid species have a well deﬁned collapse temperature188
which rises with the hydrophilicity of the respective amino189
acid: 24 ◦C for valine, 40 ◦C for proline, 45 ◦C for alanine190
and 55 ◦C for glycine [19]. Therefore, by combining different191
amino acids, it is possible to design linear homopolypeptides192
that hydrophobically collapse near the physiological tem-193
perature. These so-called ‘‘elastin-like polypeptides’’ (ELP)194
behave like PNIPPAm. For example, the LCST of an ELP made195
of Val-Pro-Gly-Val-Gly repeats is 26 ◦C [19], which is raised to196
42 ◦C by randomly substituting 50% Val, 30% Gly and 20% Ala197
for the second valine in the repeats. Such ELP may be suit-198
able for temperature-responsive drug delivery applications199
[20,21].200
It is clear from the above discussion that the phase201
transitions and the associated property changes of the202
temperature-responsive polymers are fundamentally sen-203
sitive to the chemical and structural features of their204
building blocks as well as their surrounding [1]. This205
is unavoidable because the LCST transition reﬂects a206
delicate balance between solubilization and hydrophobic207
collapse, which involve electrochemical equilibrium and208
electrostatic/electrodynamic interactions. These inﬂuence-209
exerting features start with the primary structure of the210
polymer, including the hydrophilicity/hydrophobicity of the211
monomers and their arrangement (e.g., random copolymer212
versus block copolymer). They also extend to the secondary213
structure; for example, whether the hydrophobic block is a214
random coil, -helix or -sheet makes a difference [15—16].215
Moreover, the chemistry and physical properties of the216
modiﬁcations to the polymer and its environment, includ-217
ing crosslinking agents, intentionally incorporated additives218
Figure 3 Size range of particles made of temperature-
responsive polymers, as well as that of the iron oxide particles
contained therein.
such drugs and imaging agents or unintentionally incorpo- 219
rated additives such as absorbed serum proteins, and the 220
aqueous environment it is in (pH, salt concentration and 221
dielectric constant), can all have a profound effect. Lastly, 222
the molecular weight and polydispersity of the polymer 223
are obviously important parameters as well. These factors 224
should be taken into account in the design of any materials 225
package involving temperature-responsive polymers. 226
Temperature-responsive nanocolloids 227
Although temperature-responsive polymers may be directly 228
conjugated with drugs and used as such, a preferred form 229
for controlled drug delivery entails the colloidal state in 230
which the therapeutic substance is encapsulated inside 231
the suspended nanoparticles [4]. Nanocolloids based on 232
temperature-responsive polymers must remain stable in 233
physiological electrolytes such as phosphate buffered solu- 234
tion (PBS) and serum. The typical size range of stable 235
colloids prepared from common temperature-responsive 236
polymers is shown in Fig. 3. Some examples of polymer- 237
based temperature-responsive colloidal particles are given 238
in Table 2. 239
Being an amphiphilic surfactant, PEO—PPO—PEO read- 240
ily forms oil-in-water micelles with a PPO core and a PEO 241
corona. Using double emulsion (water-in-oil-in-water) tech- 242
niques (e.g., Fig. 4), one can also form PEO—PPO—PEO 243
vesicles (liposomes or nanocapsules) with a shell made of 244
a bilayer membrane that has hydrophilic, PEO-rich outer 245
Table 2 Volume changes and transition temperatures of colloidal particles made of temperature-responsive polymers. Volume
change is generally larger for the Pluronic® series than for the PNIPAAm series. It also increases in the order of nanoparticles,
microspheres/beads and nanocapsules.
Materials Volume changes (%) Transition temperature (◦C)
PNIPAAm/iron oxide Beads [87]a ∼85 ∼35
PNIPAAm microsphere [88] ∼83 ∼35
Au/Boltorn H40-NIPAAm nanoparticle [89] ∼64 ∼32
Pluronic® F127/iron oxide nanoparticles [90] ∼78 20—25
Pluronic® F127 nanocapsules [91] ∼97 ∼26
Pluronic® F127/heparin nanocapsules [22] ∼99 ∼25
Pluronic® F127/poly(ethylenimine) nanocapsules [92] 92—97 ∼21
Au/Pluronic® F127 core—shell nanocapsules [93] ∼96 ∼18
Pluronic® F127/PEG nanocapsules [94] ∼89 ∼23
Pluronic® F68 nanocapsules [91] ∼98 ∼40
Pluronic® F68/iron oxide nanocapsules [91] ∼94 ∼40
a mm sized.
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Figure 4 A self-assembly strategy of aqueous nanocapsules using two water phases and one oil phase for drug delivery under
combined magnetic and thermal stimuli. ‘‘W1’’: a water phase made of PBS into which a hydrophilic drug and Fe salts are dissolved.
‘‘W2’’: a water phase made of PBS. ‘‘Oil’’: an oil phase made of methylene chloride solution containing PEO—PPO—PEO triblock
copolymer (e.g., Pluronic® 68). The triblock copolymer is modiﬁed by reacting 4-nitrophenyl chloroformate (NPC) with PEO forming
Pluronic®—NPC which can later react with gelatin for crosslinking. (a) Adding W1 to oil forms an inverse micelle emulsion; (b)
adding this emulsion to W2 forms a liposome suspension containing nanocapsules with a bilayer PEO—PPO—PEO shell. (c) The PEO
shell can be crosslinked by adding gelatin and held at 4 ◦C, and gelatin itself can be crosslinked by reacting with 1-ethyl-3-(3-
dimethylaminopropyl)carbodiimide (EDC) at 4 ◦C; meanwhile, the oil residue in the PEO—PPO—PEO bilayer can be removed by
evaporation. (d) Iron oxide nanoparticles can be precipitated by adding ammonia to raise pH to 10 under modest heating of 60 ◦C.
The ﬁnal F68 nanocapsule has a diameter of 108 nm at 25 ◦C and 43 nm at 50 ◦C (see Fig. 5).
faces [22]. These colloids dilate below the LCST and shrink246
above the LCST, with a radius ratio typically ranging from247
2 to 5 (Fig. 5). Post-formation crosslinking adds stability248
to the colloids without substantially affecting their ther-249
mal responses. The core of the PEO—PPO—PEO micelle can250
incorporate hydrophobic substance such as drug, as can the251
shell of the bilayer nanocapsule; meanwhile the core of252
the bilayer nanocapsule can be loaded with hydrophilic sub-253
stance as illustrated in Fig. 4.254
PNIPPAm is a homopolymer and does not self-assemble255
into micelles. However, latex-like colloids which exhibit256
volumetric responses to temperature changes can be pre-257
pared starting with NIPPAm monomers and proceeding with258
polymerization under emulsifying conditions that limit the259
reactions within emulsion micro-reactors. The product is260
often referred to as microgel [23,24] which may actually261
reach the nanosize (less than, say, 300 nm) for PNIPPAm262
[25] and PVCL [26]. More generally, PNIPPAm may be263
modiﬁed in two ways to become sufﬁciently amphiphilic,264
hence capable of self-assembly into nanocolloids [1]. First,265
when the NIPPAm blocks copolymerize with blocks that266
are more hydrophobic, the block copolymer self-assembles267
into micelles with a hydrophobic core and a PNIPPAm-rich268
corona. Conversely, when more hydrophilic pendants are269
added to NIPPAm, micelles form above the LCST with a270
PNIPPAm core and a hydrophilic corona; the micelles can271
then be crosslinked to maintain stability below the LCST.272
Triblock copolymer with both a hydrophobic end block and273
a hydrophilic end block can also be prepared [27]. A simi-274
lar approach may be applied to form ELP colloids [20]. The275
above colloids also undergo volumetric transitions with a276
typical radius ratio ranging from 2 to 4, while their cores277
can again incorporate hydrophobic drugs.278
The volume reduction of the colloid is obviously accompa-279
nied by water rejection. Accordingly, bulk or shell diffusivity280
may change signiﬁcantly. In the case of hydrogel, there281
Figure 5 Temperature-responsive transition manifested by a
diameter reduction above the LCST. F69 refers to nanocapsules
having a shell made of a bilayer of the PEO—PPO—PEO triblock
copolymer known as Pluronic® F68. Its structure is similar to
that illustrated in Fig. 4(b). F68—EDC refers to similar nanocap-
sules in which the outer PEO shell is crosslinked by gelatin,
which in turn is crosslinked by EDC. Its structure is similar to
that illustrated in Fig. 4(c). F68—IO refers to fully crosslinked
nanocapsules that additionally contain iron oxide nanoparticles
in the core as illustrated in Fig. 4(d). The LCST may be identi-
ﬁed with the inﬂection point of the size-temperature curve. The
LCST is lower in F68—EDC and F68—IO mostly because the addi-
tive (NPC, see caption of Fig. 4), which reacts with PEO to render
it crosslinkable, is less hydrophilic than PEO. Crosslinking con-
strains swelling at low temperature, so F68—EDC is smaller than
F68 below the LCST. Filling the core with iron oxide nanoparti-
cles further reduces shrinkage above the LCST.
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is evidence of a ‘‘dry skin’’ forming above the LCST that282
decreases the diffusivity [28,29]. Pronounced changes in283
surface properties are also experienced by some colloids.284
On colloids that have a PNIPPAm or ELP corona the sur-285
face switches from being hydrophilic to being hydrophobic286
as the LCST is exceeded, causing colloid to aggregate or even287
precipitate from the water solution [30]. The hydrophobic288
nanoparticles in the aggregate actually experience an addi-289
tional squeeze caused by the inter-particle adhesion and290
osmotic pressure [30]. Such hydrophobic colloids have a291
strong tendency to adhere to the living cells. These changes292
do not occur on PEO—PPO—PEO colloids which have a PEO293
corona that is always hydrophilic.294
Magnetic-core/shell295
A magnetic-core or shell as a part of the colloidal nanopar-296
ticle offers three opportunities: the magnetic colloid can297
be attracted to the region of a high magnetic ﬁeld H, it298
can experience an internal stress as non-uniform distor-299
tion arises from magnetic forces, and it can be heated by300
a non-contact magnetic ﬁeld. The attracting ﬁeld can be301
either DC or AC since the magnetic body force is the gra-302
dient of the magnetic internal energy density 1/20H2,303
where  is susceptibility and 0 is the permeability of vac-304
uum. Therefore, high-susceptibility material is favored for305
magnetic localization. On the other hand, the heating ﬁeld306
is always AC typically in the radio-frequency (RF) range,307
104 to 105 Hz. Since an AC ﬁeld can generate an eddy cur-308
rent, induction heating is always feasible for any conductor,309
but it becomes more efﬁcient for a magnetic material in310
which magnetic hysteresis causes additional energy dissipa-311
tion. To maximize the sum of eddy current (Joule) heating312
and magnetic heating, a relatively high electrical resistivity313
and large magnetic coercivity (mainly due to the resistance314
to domain wall movement) is therefore favored. However,315
nanomagnets suitable for nanocolloids are superparamag-316
netic [31], i.e., it is a single-domain ferromagnet free to317
switch following a quasi-static ﬁeld without apparent coer-318
civity. So there is little coercivity contribution and whatever319
energy dissipation must come from some sort of internal320
or boundary ‘‘friction’’ (see below) which does not pre-321
vent switching but nevertheless drags the magnetic moment322
letting it lag the AC ﬁeld. In a linear-response medium,323
the Debye theory describes this lag in terms of a relax-324
ation time  [32]. It then follows that maximal dissipation325
occurs when −1 is commensurate with the frequency f, i.e.,326
2f∼ 1, because when 2f 1 there is no lag and when327
2f 1 the moment stops to respond. Therefore, effec-328
tive heating obtains by tuning the frequency to the range of329
2f∼ 1; under this condition more heat can be generated330
by driving the ﬁeld harder (higher H) and faster (higher f).331
Lastly, magnetic distortion can be caused by either a DC or332
AC ﬁeld as long as the frequency is not much higher than333
the resonance frequency. There is little knowledge of the334
magneto-mechanical resonance of colloidal nanoparticles335
although typical experiments utilizing magnetic distortion336
are conducted with a frequency much less than 103 Hz, a337
condition unlikely to contribute to much heating.338
Among magnetic metals Co is perhaps the only material339
suitable for the magnetic-core or shell; Fe oxidizes too easily340
at the nanosize and Ni is toxic to the body. Among mag- 341
netic oxides iron oxide (IO) is preferred. Iron oxide takes 342
the form of magnetite (Fe3O4) or maghemite (-Fe2O3), both 343
having the structure of spinel although -Fe2O3 is a highly 344
defected spinel containing many vacancies in the sublat- 345
tices of both Fe3+ and O2−. Maghemite IO is clinically used 346
as a contrast agent for magnetic resonance imaging (MRI) 347
because it causes a (dipolar-type) ﬁeld inhomogeneity which 348
accelerates the spin-spin relaxation/decoherence in its sur- 349
rounding [33]. The use of other ferrites, such as magnetic 350
spinels with other 3d transition metals partially substituting 351
for Fe [34,35] and haxaferrites such as BaFe12O19 [36], is not 352
advised because of increased complexity for synthesis and 353
uncertain proﬁle of toxicity. 354
Since all the above oxides are insulators, only Co may 355
beneﬁt from eddy current heating. However, no report exists 356
for incorporating Co into nanosized temperature-responsive 357
polymer colloid (Co-containing micelles made of other block 358
copolymers have been reported [37]). The strategy to incor- 359
porate IO into the core of a temperature-responsive polymer 360
colloid varies according to the nature of the core. In an aque- 361
ous solution, IO nanoparticles readily form from Fe(II) and 362
Fe(III) salts at ambient or near ambient temperatures. After 363
puriﬁcation and recovery, the redispersed IO in an aqueous 364
solution may be used as one part of the feedstock in the 365
double-emulsion procedure to form the hydrophilic core of 366
a PEO—PPO—PEO colloid (Fig. 4(a,b)). Alternatively, inter- 367
nal precipitation in the hydrophilic core which contains a 368
Fe(II)/Fe(III) solution may be triggered by a pH increase 369
after the formation of the colloid (Fig. 4(e)). For hydropho- 370
bic cores, hydrophobic IO nanoparticles need to be ﬁrst 371
synthesized, which typically involves high temperature pre- 372
cipitation in a long-chain alcohol such as oleic acid [38,39]. 373
The oily IO can then be used in the emulsion procedure to 374
enter the hydrophobic core. Since the procedure to grow 375
spherical oily IO nanoparticles of a narrow size distribution 376
from 3 to 20 nm (Fig. 6(a—d)) is rather well developed, it may 377
also be used to prepare hydrophilic IO if it is modiﬁed with an 378
additional step to introduce a hydrophilic outer coat using 379
ligand exchange, physical adsorption or chemical conjuga- 380
tion [40,41]. Magnetic-shells containing IO are also possible. 381
Since most shells of temperature-responsive polymer col- 382
loids are hydrophilic, magnetic-shells are synthesized using 383
hydrophilic IO. This is typically achieved by either adsorp- 384
tion of IO nanoparticles or precipitation from aqueous 385
Fe precursors [26,42]. Using IO nanoparticles as seeds to 386
initiate polymerization, other magnetic-core/polymer-shell 387
nanocolloids can also be synthesized as reviewed by Schmidt 388
[31]. 389
Under magnetic heating the temperature of the mag- 390
netic nanocolloid solution gradually rises reaching a steady 391
state of several to several tens of degrees of centigrade 392
higher. At this temperature, the heat input from the mag- 393
netic nanoparticles equals the heat loss at the external 394
boundary (the container, ﬁxtures, surfaces). What is infor- 395
mative of magnetic dissipation is the initial heating rate, 396
typically of the order of 0.1—1 ◦C/s for colloids containing 397
IO nanoparticles. Since the energy input of the solution is 398
entirely from the energy input of the magnetic nanopar- 399
ticles, the initial heating rate of the nanoparticle should 400
be precisely CW/CMVM times that of the (water) solution. 401
Here CW and CM are the volumetric speciﬁc heat of water 402
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Figure 6 Morphologies, revealed by transmission electron microscopy, of iron oxide nanoparticles prepared from an oil-based
solution. (a and b) are solid particles and (c and d) are hollow ones. The as-prepared nanoparticles are single crystals according to
lattice imaging (b) and (d). (e) After magnetic heating, some hollow nanoparticles ruptured into pieces no longer in registry with
each other, as indicated by markers.
and the magnetic material, respectively, and VM is the vol-403
ume fraction of the magnetic material in the solution. Since404
CW/CM ∼ 1 for IO and VM is of the order of 10−3, the initial405
heating rate experienced by the IO nanoparticle must be of406
the order of 102 to 103 ◦C/s. The steady state temperature407
of the IO nanoparticle depends on the heat exchange mech-408
anisms between IO and the surrounding, which are currently409
unknown. However, microscopy evidence presented in Fig. 7410
for IO nanoparticles in the core of a PEO—PPO—PEO colloid411
after RF heating suggests a rather high temperature of pos-412
sibly several hundred degrees of centigrade. Clearly, very413
efﬁcient ‘‘frictional’’ heating has been achieved. Magneti-414
cally caused fracture of hollow IO nanoparticles is also seen415
in Fig. 6(e), and similar transmission electron microscopy416
observations of magnetic-heat-rupture have been reported 417
for silica nanoparticles coated with an (single crystalline) IO 418
shell [43]. 419
Assuming magnetic heating involves isolated, indepen- 420
dent nanoparticles only, in an RF ﬁeld friction arises in and 421
around a magnetic particle from two sources [44]. First, 422
particle may tumble causing frictional heating at the par- 423
ticle—water interface. The relaxation time B for this mode 424
can be estimated as the time required for Brownian motion 425
over a characteristic distance of the order of one particle 426
diameter. From Stoke—Einstein equation and viscous drag on 427
a spherical particle, one can estimate B = 3V/kT, where  428
is the viscosity at the interface, V is the particle volume and 429
kT has its usual meaning. Brownian relaxation may not be 430
Figure 7 Transmission electron micrographs of F68—IO nanocapsules (see caption of Fig. 5) that show (a) uneven shrinkage after
exposure to 45 ◦C, above the LCST. After magnetic heating, some nanocapsules ruptured (b), other coarsened into irregular shaped
ones (c).
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responsible for the frictional heating of IO seen in Fig. 7,431
though, because the heat from this mechanism should be432
about equally shared between the nanoparticle and water so433
it is unlikely for IO alone to reach a very high temperature.434
Friction may also arise from spin rotation without crystal-435
lattice rotation. The relaxation time N for this mode (Neel436
relaxation) is the reciprocal of the spin ﬂipping rate which437
is of the order of D exp(−KV/kT). Here D is the Debye fre-438
quency of the order of 1012/s and KV is the energy barrier for439
coherent spin ﬂipping which may be of a magnetocrystalline440
or shape origin. Most IO nanoparticles of several nanometers441
in size are superparamagnetic with a blocking temperature442
typically around 50 K or lower. At the blocking temperature,443
N should be of the order of 10−2 to 102 s, so we estimate444
N to be of the order of 10−10 s at room temperature. This445
would make Neel relaxation too fast to add to any signiﬁcant446
friction in a RF ﬁeld. However, the IO nanoparticles in Fig. 7447
came from internal precipitation at the ambient tempera-448
ture, so they are not perfect and most likely contain a high449
concentration of crystalline defects. Such defects may not450
signiﬁcantly affect the blocking temperature and the super-451
paramagnetic characteristics measured at low frequency,452
but they can greatly increase the friction against spin ﬂip-453
ping thus causing lattice heating. This seems to be the most454
likely magnetic heating mechanism for the IO nanoparticles455
in Fig. 7.456
Biomedical applications457
Magnetically and thermally responsive nanocolloids may ﬁnd458
applications in medicine and biotechnology such as drug459
delivery and enzyme immobilization/separation. Magnetic460
body force can align or relocate the colloid and magnetic461
dissipation provides a means of remote heating. Temper-462
ature excursions can trigger a change in the size, water463
content, diffusivity, surface properties and hydrogen bond-464
ing of the colloid. Although all of these individual effects465
have been separately illustrated in numerous studies, there466
are very few biomedically relevant reports that demonstrate467
the combined magnetic and thermal actions in the nanocol-468
loid setting—–bulk hydrogels and large (m to mm) latex469
particles are excluded. In the following, we summarize these470
studies and comment on the pertinent mechanisms.471
Magnetic heating of UCST colloids472
Conventional synthetic polymers may experience increased473
diffusivity and water content when magnetically heated474
above the UCST, which may accelerate the release475
of trapped drug or a model dye. This was reported476
by Schmidt and coworkers for an IO-core-containing477
poly(-caprolactone) (PCL) nanocolloid loaded with a solva-478
tochromic dye; PCL exhibits an UCST of 35 ◦C when dispersed479
in dimethyl sulfoxide as in this study [45,46]. A more inter-480
esting study concerns a biopolymer with hydrogen bonding481
that melts above the UCST; magnetic heating then causes482
the release of hydrogen-bonded drug. This was demon-483
strated by Derfus et al. using IO nanoparticles to which single484
strand DNA was grafted: the DNA binds a dye-labeled com-485
plement below the UCST, then releases it above the UCST486
at the implanted site in a mouse tumor model [47]. Melting487
Figure 8 Cumulative release of a model drug (vitamin B12)
from F68—IO nanocapsules (see caption of Fig. 5) at various
temperatures. The rapid increase from 37 to 45 ◦C is mostly
due to nanocapsule shrinkage from 90 to 45 nm (see Fig. 5). The
much faster burst-like release during magnetic heating is due
to rupture of the nanocapsule (see Fig. 7).
hydrogen-bonding in a bulk gel magnetically heated above 488
the UCST has been used to increase the diffusivity, hence 489
drug release from IO-containing collagen [48] and gelatin 490
[49]. Extension to microgels of submicrometer sizes is in 491
principle feasible but not yet reported. 492
Magnetic heating of LCST colloids 493
Magnetic heating of the NIPPAm colloid above the LCST 494
induces aggregation and size shrinkage. Wakamatsu et 495
al. [50] applied the ﬁrst effect to IO-core/PNIPPAm-shell 496
nanoparticles to trigger their entrapment in a column 497
packed with hydrophobic beads. We have applied the sec- 498
ond effect to PEO—PPO—PEO nanoparticles to squeeze out 499
a hydrophilic drug from the core (the preparation method 500
is shown in Fig. 4, size isotherm in Fig. 5, reconstructed 501
magnetic-cores in Fig. 7, and the release mechanism in 502
Fig. 1). This is the ﬁrst example of utilizing magnetic heating 503
and size shrinkage to control drug release from a nanocol- 504
loid. The proﬁle of drug release rates shown in Fig. 8 is 505
very favorable: very slow at 4 ◦C and 25 ◦C, modest at 37 ◦C 506
(below the LCST), much faster at 45 ◦C (above the LCST) 507
and bursting upon magnetic heating. Compared to an earlier 508
example of m-sized colloid (NIPPAm with IO) [51], the ratio 509
of release under magnetic heating to that of 25 ◦C is at least 510
a factor of 100 higher in this nanocolloid. A further com- 511
parison to other examples of magnetically triggered drug 512
release (with or without a temperature-responsive polymer) 513
is shown in Table 3. 514
Magnetic separation of LCST/UCST colloids 515
Magnetic support particles have been investigated for a long 516
time as a separation platform in biotechnology. Nanometer 517
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Table 3 Half-life (t50) for drug release (typically a small molecule) from particles with and without magnetic heating. t50 is
the time to reach Mt/M∞ = 0.5, where Mt/M∞ is the amount released at time t normalized by the total amount of drug contained
(see Fig. 8). Much faster release with magnetic heating.
Materials Half-time (t50)a Released molecules
Without magnetic heating With magnetic heating
Pluronic® F68/iron oxide
nanocapsules [91]
42 h (37 ◦C)/5 h (45 ◦C) 5min Vitamin B12
Pluronic® F127/iron oxide
nanoparticles [90]
18 h (15 ◦C)/3 h (45 ◦C) 5min Doxorubicin
Fe3O4/PAH capsules [95]a 15 h (25 ◦C) 30min FITC—dextran
Silica/iron oxide nanospheres [43]a >20 days (25 ◦C) 3min Fluorescent dye
Silica/iron oxide nanospheres [96]a >10 days (25 ◦C) 15min Ibuprofen
Ethylene—vinyl acetate with
embedded magnetic sphere [97]b
Not measured (>40 days) 10 times shorterb Bovine serum albumin
a Without a temperature-responsive polymer.
b 10mm× 10mm× 2mm, not a temperature-responsive polymer, no magnetic heating, faster response due to magnetic distortion.
sized colloids can reduce fouling, but magnetic separation518
becomes much more difﬁcult because of the smaller mag-519
netic force in comparison to colloidal forces that favor520
suspension and Brownian motion. Colloids made of LCST521
polymers aggregate above the LCST, so they experience a522
much larger magnetic force and smaller colloidal forces,523
thus allowing easy separation by a relatively low ﬁeld. This524
has been demonstrated by Kondo and Fukuda [52] by heating525
IO-containing PNIPPAm colloids (150—250 nm) above 32 ◦C to526
separate immobilized enzymes on the nanoparticles. The527
dispersion-to-ﬂocculation transition at the LCST was also528
utilized by the same group [53] to achieve magnetically529
aided afﬁnity selection of target cells from phage display530
libraries. Similarly, magnetic separation of UCST colloids can531
be practiced below the UCST as illustrated by Kaiser [54] for532
IO-containing polystyrene nanoparticles. In the latter case,533
a hydrophobic solution (cyclohexane in this study) must be534
used.535
Magnetic directing of LCST colloids536
In vivo localization of nanomagnetic particles is feasible537
according to the study of Deng et al. [55] who localized IO-538
containing PNIPPAm nanoparticles (300—500 nm) to liver in539
a rabbit using a DC magnetic ﬁeld; without a ﬁeld accu-540
mulation in other organs (lung, spleen, kidney and heart)541
was observed. The colloid was initially placed below the542
LCST to access the swollen state to soak up doxorubicin,543
a hydrophilic drug for cancer treatment, although in vivo544
demonstration of drug release was not performed in this545
study apparently because the LCST (32—37 ◦C) is no higher546
than the body temperature. In principle, AC magnetic heat-547
ing (hyperthermia) can also provide a localization effect548
for LCST colloids since above the LCST the colloid will pre-549
cipitate with a tendency to adhere to the cells. Localized550
hyperthermia was proposed as a targeting tool to direct551
drug-loaded LCST colloids to tumors which are warmer552
(∼42 ◦C) than the rest of the body [30], but this idea has553
not been demonstrated for magnetic colloids.
Membranes of magnetically and thermally 554
responsive colloids 555
Various magnetic hydrogels not unlike those previously 556
mentioned [48—49] have been studied but one serious short- 557
coming of the macroscopic gels is their slow response 558
time, which scales with the size to the second power 559
reﬂecting the diffusion limit of water transport [56]. This 560
can be overcome if the macroscopic construct is itself 561
made of nanoparticles of temperature-responsive hydro- 562
gel. Since the diffusion time of nanoparticle is very short, 563
the response of the construct is also very fast despite 564
its macroscopic dimension. Indeed, the nanoparticles can 565
even be embedded in another gel without affecting the 566
response time as long as water exchange in and out of 567
the nanoparticles can proceed locally. One such construct 568
with a magnetic signature is a membrane made by gelling 569
nanoparticles or by depositing nanoparticle colloids. For 570
example, Csetneki et al. reported a membrane made of 571
nanoparticles with an IO-containing polystyrene core which 572
is coated with PNIPPAm [57]. The membrane was endowed 573
with a special microstructure by applying a magnetic ﬁeld 574
during gelation (below the LCST) with poly(vinyl alcohol) 575
crosslinking: the magnetic nanoparticles are lined up into 576
necklace strings due to dipole—dipole interactions. Above 577
the LCST, shrunk nanoparticles disrupt the microstructure 578
causing a rapid increase in permeability as demonstrated 579
by bovine serum albumin penetration. Using spin coat- 580
ing, we have fabricated a 50-m ﬁlm of IO-containing 581
PEO—PPO—PEO nanoparticles on a silicon substrate to 582
demonstrate magnetically actuated rapid dye release from 583
this device (Fig. 9). Micro-implant devices constructed in a 584
similar way may be used for magnetically controlled drug 585
delivery. 586
In vivo delivery 587
Hyperthermia via magnetically heating of IO has been stud- 588
ied in mice and human cadavers to treat breast tumors, 589
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Figure 9 A device prototype made of iron-oxide-containing nanocapsules. Drug-containing F68—IO nanocapsules (see caption of
Fig. 5) were spin coated onto a Si substrate to form a 60-m thick ﬁlm. Another PEO—PPO—PEO triblock polymer (Pluronic® F127)
solution with a LCST of 22 ◦C was used in the spin-coating solution as a ‘‘binder’’ gel. After spin coating, a gelatin coating was
introduced to crosslink the PEO shell of the nanocapsule. Magnetic heating triggers drug release from F68—IO. A similar implant
device may be used for controlled drug release.
showing tumor shrinkage and nuclear degenerations in590
heated malignant cells [58]. A maximum temperature ele-591
vation T up to 88 ◦C was reported. A recent study592
demonstrated deep cranial thermotherapy using magnetic593
heating of aminosilane-coated IO applied to human glioblas-594
toma multiforme patients who also received MRI and595
computed tomography (CT) for evaluation [59]. At a T of596
5—12 ◦C, patients reported no discomfort. For drug release,597
we already mentioned (see Magnetic heating of UCST col-598
loids section) the study of ﬂuorophore (a model drug) release599
from magnetically heated IO that was pre-implanted into600
a mouse tumor model [47]. Clinical use of dextran-coated601
IO as a MRI contrast agent has also been a well-established602
modality for liver imaging [33].603
In the above applications IO colloids were delivered by604
direct injection to the target sites. In recent years, in605
vivo animal studies have been used to demonstrate the606
possibility of targeted delivery and imaging of IO with teth-607
ered targeting moieties; for example, folate ligand has608
been tethered to the dextran coating of IO via a linker609
to target tumor xenografts that overexpress folate recep-610
tors [60]. In theory, if the self-directed IO colloids are611
well localized to the targeted tumor site, they can also612
be magnetically heated to treat tumor, but this has not613
been demonstrated in vivo. Indeed, although multifunc- 614
tional nanoparticles capable of targeted delivery of imaging 615
agents and drugs is a much discussed concept, its in vivo 616
demonstration for magnetic colloids is so far rare; we know 617
of none for temperature-responsive magnetic colloids. In a 618
recent review of application of nanotechnology in cancer 619
therapy and imaging [61], only one was cited for simultane- 620
ous targeted delivery of drug and imaging agent: it delivers 621
to targeted tumor cells small interfering ribonucleic acids 622
(siRNA) that are covalently tethered to the dextran coat- 623
ing of IO [62]. This study did not utilize magnetic heating, 624
magnetic directing or thermal sensitivity. Recently, Yang et 625
al. used core-shell magnetic nanoparticles (core containing 626
MnFe2O4, a spinel ferrite and doxorubicin, an anticancer 627
drug) tethered with a breast-cancer-targeting antibody 628
(human epidermal growth factor receptor 2 (HER2)) to 629
simultaneously detect and treat cancer xenografts in mouse 630
models [63]. Although this study used an amphiphilic block 631
copolymer of poly(D,L-lactide-co-glycolide) (PLGA) and PEG 632
for the shell, which is not temperature-responsive, it should 633
be possible to replaced PLGA—PEG by PEO—PPO—PEO or a 634
PNIPPA copolymer. Using such a construct, functionalities of 635
magnetic heating, magnetic directing and thermal sensitiv- 636
ity can in principle be incorporated into nanocolloid systems 637
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for self-directed simultaneous detection and treatment of638
diseases.639
Designing nanoscale systems640
We begin this section with a few comments on the drug641
release mechanisms in magnetically heated LCST colloids.642
Although a generic increase in diffusivity at higher tempera-643
ture may play a minor role, the dominant mechanisms are all644
related to structural changes due to the LCST transition and645
magnetic ﬁeld/heating. Clearly, the volumetric shrinkage646
provides a potentially powerful driving force for drug release647
from the core. Effective actuation requires core shrinkage,648
which is easier for a soft core than for a hard core [64].649
However, volumetric shrinkage cannot account for the mag-650
netically triggered burst-like release in Fig. 8, which is much651
faster than that achieved by heating to 45 ◦C (above the652
LCST) alone. The burst-like release is most likely due to the653
severe disruption of the IO core by magnetic heating. Other654
structural changes in the pore structure of the shell may also655
play a role. The changes may be caused by a thermal distor-656
tion akin to the one associated with a heated heterogeneous657
network structure: some regions expand while others con-658
tract. Magnetic forces may also cause a structural disruption659
of the shell when 2fB  1, as shown in a low frequency660
(300Hz) study on magnetically triggered on—off permeabil-661
ity switch across a polyelectrolyte shell surrounding a Co/Au662
core of 5m [65]. Force-directed structural movement is663
probably not important in the RF frequency range because,664
to effect shell distortion, 2fB  1 must be satisﬁed for665
a particle of the size of the colloidal particle—–a condition666
unlikely to be met.667
We have already emphasized the importance of the668
LCST/UCST temperature, the structural transitions and the669
magnetic constituent of the nanocolloid that is responsive670
to both magnetic and temperature stimuli. For in vivo drug671
delivery, these temperatures should be a few degrees of672
centigrade above the physiological temperature, and prefer-673
ably there is a large change in size and surface functionality.674
Tuning the transition temperature must be tackled at the675
system level, since as mentioned before the transition tem-676
perature is sensitive to all chemical and physical aspects677
of the constituents of the polymer and its surrounding. A678
soft core is preferred to effect core shrinkage [64]. Actu-679
ation will be more effective if the transition temperature680
and the magnetic response are sharp. This requires a pre-681
cise control of the composition and microstructure including682
a narrow distribution of the molecular weight of the polymer683
and of the size of the IO nanoparticles. Efﬁciency of mag-684
netic heating is probably sensitive to the defect chemistry685
of the IO, its control and characterization at the nanoscale686
presenting a challenge. Cost, synthetic ease and scalability687
for mass production are important and mostly dependent on688
the chemistry and processes selected.689
A successful system design should also address other690
issues of material chemistry and physics. First, safety and691
biocompatibility demand rigorous screening to eliminate692
any toxic chemical in the composition of the polymer693
and the process residue. A particularly complicated issue694
is colloidal and drug stability. Structural integrity of the695
nanocolloid obviously calls for substantial stability of the696
constituent polymer during storage and circulation, which 697
may be improved by crosslinking. Nanocolloids tend to have 698
longer circulation half-lives, but to help escape the fate 699
of rapid clearance by macrophages or the reticuloendothe- 700
lial system surface hydrophilic tethers of PEG or dextran (a 701
polysaccharide) are beneﬁcial [66]. Tethers may also reduce 702
the absorption of serum proteins, thus avoiding enzymatic 703
attack at the same time. Meanwhile, biodegradability of the 704
temperature-responsive polymer would be desirable which 705
may be introduced by incorporating biodegradable blocks 706
or oligomers such as PCL [67], polylactic acid (PLA) [68] and 707
PLGA [69], including their copolymers (in the PEO—PPO—PEO 708
triblock copolymers, they should substitute for the PPO 709
block) [60]. Concerning drug targeting, hydrophilic tethers 710
mentioned above will mask the transition to hydrophobicity 711
above the LCST of PNIPPAm and PVCL, so temperature- 712
triggered aggregation and cell adhesion is no longer possible. 713
In this regard, moieties for receptor or ligand bonding to 714
enable targeted delivery is a desirable functionality that 715
can be attached to the nanoparticles via suitable surface 716
tethers [61]. Another important issue is the trigger for 717
drug release. Although a long residence time after local- 718
ization at the target site may sometimes be enough for 719
delivering drug, a more efﬁcient scheme is to utilize a 720
device that allows for nanoparticle internalization (e.g., 721
via receptor-mediated endocytosis) [70] and drug release 722
(e.g., via an acid-labile linkage that is broken in the low- 723
pH environment of endosomes) [71,72]. Lastly, drug loading 724
is dictated by the physical chemistry of the polymer and 725
the drug during fabrication, so a condition which simultane- 726
ously allows for polymer reaction (including self-assembly) 727
and drug incorporation need to be found [64]. Since these 728
aspects will again impact the transition temperature and 729
transition characteristics, a system engineering approach 730
must be adopted to ﬁnd a satisfactory solution for this 731
nanotechnology. 732
Finally, injection of particulate substance (liposomes, 733
micelles and other natural or synthetic particles) in the 734
submicron size range may elicit allergic reactions such as 735
cardiovascular, respiratory and cutaneous symptoms, includ- 736
ing death [73]. Typically, such reactions are most severe 737
upon initial exposure, and the frequency of particulate 738
allergy in the 5—45% range seems to be much higher than 739
that of classical anaphylactic reactions to drugs (for exam- 740
ple, penicillin allergy occurs in <2%). Interestingly, the 741
trigger dose of hypersensitivity reactions in mouse mod- 742
els is two orders of magnitude higher than that in reactive 743
man, so many animal studies may not foretell the threat of 744
possible allergic reactions (interestingly, pig models appear 745
to exhibit a similar trigger dose as reactive man). There- 746
fore, designing safe nanoparticle delivery systems for in 747
vivo applications may pose the most serious though least 748
considered challenge. 749
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